RT Journal Article
T1 Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
A1 Provencio, Mariano
A1 Rodríguez-Abreu, Delvys
A1 Ortega, Ana L
A1 Serrano, Gloria
A1 Aguado, Carlos
A1 Franco, Fernando
A1 Gutierrez, Vanesa
A1 López Vivanco, Guillermo
A1 Guirado, María
A1 Benítez, Gretel
A1 Estival, Anna
A1 Calvo, Virginia
A1 Jiménez, Beatriz
A1 Arasanz, Hugo
A1 Coves, Juan
A1 Majem, Margarita
A1 Massutí, Bartomeu
A1 Vázquez, Sergio
A1 Juan-Vidal, Oscar
A1 Collazo-Lorduy, Ana
A1 Gozálvez, Clara L
A1 Del Barco, Edel
A1 Rosero, Adriana
A1 Bosch-Barrerra, Joaquim
A1 Moreno, María A
A1 Mielgo-Rubio, Xabier
A1 Villa, José C
A1 López-Martin, Ana
A1 Córdoba, Juan F
A1 de Asís Aparisi, Francisco
A1 Zafra, Marta
A1 Mosquera, Joaquín
A1 Pérez Altozano, Javier
A1 Nadal, Ernest
A1 Catot, Silvia
A1 Balsalobre, José
A1 de Portugal, Teresa
A1 Martín, Paloma
A1 Cuesta de Juan, Susanaa
A1 Cobo, Manuel
K1 Immunity
K1 lung cancer
K1 seroprevalence
K1 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AB At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. ClinicalTrials.gov identifier: NCT04407143.
SN 2218-6751
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21776
UL http://hdl.handle.net/10668/21776
LA en
DS RISalud
RD Apr 9, 2025